(Q34330761)

1 August 2017

title

Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature (English)

1 reference

1 August 2017

Bradley M Wright

1

1 reference

1 August 2017

Edward H Eiland

series ordinal

2

1 reference

1 August 2017

Raymond Lorenz

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

33

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

344-359

1 reference

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

1 August 2017

cites work

1 reference

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

21 January 2018

1 reference

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

Receptor mechanisms in the treatment of schizophrenia.

21 January 2018

1 reference

Use of atypical antipsychotics for treatment-resistant major depressive disorder

21 January 2018

1 reference

An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression

21 January 2018

1 reference

Aripiprazole as an adjunctive treatment for refractory unipolar depression

21 January 2018

1 reference

An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression.

21 January 2018

1 reference

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

21 January 2018

1 reference

Clozapine in medication- and electroconvulsive therapy-resistant, depressed inpatients: a case series

21 January 2018

1 reference

Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series

21 January 2018

1 reference

Effect of augmentation with olanzapine in outpatients with depression in partial remission with melancholic features: consecutive case series

21 January 2018

1 reference

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

21 January 2018

1 reference

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

21 January 2018

1 reference

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

Quetiapine augmentation in depressed patients with partial response to antidepressants.

21 January 2018

1 reference

Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study

21 January 2018

1 reference

Quetiapine augmentation in treatment-resistant depression: a naturalistic study.

21 January 2018

1 reference

Quetiapine augmentation of treatment-resistant depression: a comparison with lithium

21 January 2018

1 reference

A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety

21 January 2018

1 reference

A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.

21 January 2018

1 reference

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled st

21 January 2018

1 reference

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

21 January 2018

1 reference

Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression

21 January 2018

1 reference

Risperidone for treatment-refractory major depressive disorder: a randomized trial

21 January 2018

1 reference

A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression

21 January 2018

1 reference

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study

21 January 2018

1 reference

Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression

21 January 2018

1 reference

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

Early predictors of substantial weight gain in bipolar patients treated with olanzapine

21 January 2018

1 reference

A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report

21 January 2018

1 reference

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

Hyperthermia syndromes in psychiatry

21 January 2018

1 reference

Tardive dyskinesia: clinical presentation and treatment

21 January 2018

1 reference

Pharmacist-designed and -implemented pharmaceutical care plan for antipsychotic-induced movement disorders.

21 January 2018

1 reference

Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects

21 January 2018

1 reference

Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder

21 January 2018

1 reference

Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors

21 January 2018

1 reference

21 January 2018

The Serotonin Syndrome

1 reference

Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report

21 January 2018

1 reference

Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1204

1 reference

1 August 2017

1 reference